Skip to main content
Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model

Fig. 5

Changes in serum and urinary cytokine profiles following treatment of tumor bearing mice. a Serum cytokines—Serum samples collected 3 days after week 1 treatment from female mice bearing tumors were compared among the six treatment groups. Serum levels of a panel of cytokines were measured by the 9-plex customized mouse cytokine Luminex assay (R&D Systems). IVe BCG treatment alone was noted to induce TNFα and IL13 compared to PBS control. Combination SQ ALT-803 and IVe BCG was noted to induce TNFα, IL5, IL6 and IL13 compared to PBS control. Interestingly, ALT-803 SQ alone, IVe BCG + IVe ALT-803 and IVe BCG + SQ ALT-803 resulted in a reduction in interleukin 1β. b Urine cytokines—Voided urine samples collected 3 days after week 1 treatment from female mice bearing tumors were compared among the six treatment groups. Urine levels of a panel of cytokines were measured by the 9-plex customized mouse cytokine Luminex assay. IVe BCG alone resulted in an induction of IFNγ compared to PBS control. However, IVe BCG + SQ ALT-803 resulted in an induction of IL13 and IFNγ

Back to article page